Cargando…

The Discovery of LOX-1, its Ligands and Clinical Significance

LOX-1 is an endothelial receptor for oxidized low-density lipoprotein (oxLDL), a key molecule in the pathogenesis of atherosclerosis.The basal expression of LOX-1 is low but highly induced under the influence of proinflammatory and prooxidative stimuli in vascular endothelial cells, smooth muscle ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimoto, Ryo, Fujita, Yoshiko, Kakino, Akemi, Iwamoto, Shin, Takaya, Tomohide, Sawamura, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204104/
https://www.ncbi.nlm.nih.gov/pubmed/21805404
http://dx.doi.org/10.1007/s10557-011-6324-6
_version_ 1782215179828723712
author Yoshimoto, Ryo
Fujita, Yoshiko
Kakino, Akemi
Iwamoto, Shin
Takaya, Tomohide
Sawamura, Tatsuya
author_facet Yoshimoto, Ryo
Fujita, Yoshiko
Kakino, Akemi
Iwamoto, Shin
Takaya, Tomohide
Sawamura, Tatsuya
author_sort Yoshimoto, Ryo
collection PubMed
description LOX-1 is an endothelial receptor for oxidized low-density lipoprotein (oxLDL), a key molecule in the pathogenesis of atherosclerosis.The basal expression of LOX-1 is low but highly induced under the influence of proinflammatory and prooxidative stimuli in vascular endothelial cells, smooth muscle cells, macrophages, platelets and cardiomyocytes. Multiple lines of in vitro and in vivo studies have provided compelling evidence that LOX-1 promotes endothelial dysfunction and atherogenesis induced by oxLDL. The roles of LOX-1 in the development of atherosclerosis, however, are not simple as it had been considered. Evidence has been accumulating that LOX-1 recognizes not only oxLDL but other atherogenic lipoproteins, platelets, leukocytes and CRP. As results, LOX-1 not only mediates endothelial dysfunction but contributes to atherosclerotic plaque formation, thrombogenesis, leukocyte infiltration and myocardial infarction, which determine mortality and morbidity from atherosclerosis. Moreover, our recent epidemiological study has highlighted the involvement of LOX-1 in human cardiovascular diseases. Further understandings of LOX-1 and its ligands as well as its versatile functions will direct us to ways to find novel diagnostic and therapeutic approaches to cardiovascular disease.
format Online
Article
Text
id pubmed-3204104
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-32041042011-11-10 The Discovery of LOX-1, its Ligands and Clinical Significance Yoshimoto, Ryo Fujita, Yoshiko Kakino, Akemi Iwamoto, Shin Takaya, Tomohide Sawamura, Tatsuya Cardiovasc Drugs Ther Article LOX-1 is an endothelial receptor for oxidized low-density lipoprotein (oxLDL), a key molecule in the pathogenesis of atherosclerosis.The basal expression of LOX-1 is low but highly induced under the influence of proinflammatory and prooxidative stimuli in vascular endothelial cells, smooth muscle cells, macrophages, platelets and cardiomyocytes. Multiple lines of in vitro and in vivo studies have provided compelling evidence that LOX-1 promotes endothelial dysfunction and atherogenesis induced by oxLDL. The roles of LOX-1 in the development of atherosclerosis, however, are not simple as it had been considered. Evidence has been accumulating that LOX-1 recognizes not only oxLDL but other atherogenic lipoproteins, platelets, leukocytes and CRP. As results, LOX-1 not only mediates endothelial dysfunction but contributes to atherosclerotic plaque formation, thrombogenesis, leukocyte infiltration and myocardial infarction, which determine mortality and morbidity from atherosclerosis. Moreover, our recent epidemiological study has highlighted the involvement of LOX-1 in human cardiovascular diseases. Further understandings of LOX-1 and its ligands as well as its versatile functions will direct us to ways to find novel diagnostic and therapeutic approaches to cardiovascular disease. Springer US 2011-08-02 2011 /pmc/articles/PMC3204104/ /pubmed/21805404 http://dx.doi.org/10.1007/s10557-011-6324-6 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Yoshimoto, Ryo
Fujita, Yoshiko
Kakino, Akemi
Iwamoto, Shin
Takaya, Tomohide
Sawamura, Tatsuya
The Discovery of LOX-1, its Ligands and Clinical Significance
title The Discovery of LOX-1, its Ligands and Clinical Significance
title_full The Discovery of LOX-1, its Ligands and Clinical Significance
title_fullStr The Discovery of LOX-1, its Ligands and Clinical Significance
title_full_unstemmed The Discovery of LOX-1, its Ligands and Clinical Significance
title_short The Discovery of LOX-1, its Ligands and Clinical Significance
title_sort discovery of lox-1, its ligands and clinical significance
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204104/
https://www.ncbi.nlm.nih.gov/pubmed/21805404
http://dx.doi.org/10.1007/s10557-011-6324-6
work_keys_str_mv AT yoshimotoryo thediscoveryoflox1itsligandsandclinicalsignificance
AT fujitayoshiko thediscoveryoflox1itsligandsandclinicalsignificance
AT kakinoakemi thediscoveryoflox1itsligandsandclinicalsignificance
AT iwamotoshin thediscoveryoflox1itsligandsandclinicalsignificance
AT takayatomohide thediscoveryoflox1itsligandsandclinicalsignificance
AT sawamuratatsuya thediscoveryoflox1itsligandsandclinicalsignificance
AT yoshimotoryo discoveryoflox1itsligandsandclinicalsignificance
AT fujitayoshiko discoveryoflox1itsligandsandclinicalsignificance
AT kakinoakemi discoveryoflox1itsligandsandclinicalsignificance
AT iwamotoshin discoveryoflox1itsligandsandclinicalsignificance
AT takayatomohide discoveryoflox1itsligandsandclinicalsignificance
AT sawamuratatsuya discoveryoflox1itsligandsandclinicalsignificance